SCHEMBL8510375

SCHEMBL8510375

O=C(O)N1CCN(c2ccc(N3CCC4(CC3)OCCO4)cn2)c2ccccc21

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 14/20 0.65
HSD11B2 P80365 1/20 0.42
PTPN11 Q06124 1/20 0.42
F12 P00748 1/20 0.41
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 1/20 0.38
MEN1 O00255 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LGMN Q99538 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9982587 0.86 HSD11B1 (0.63) HSD11B1HSD11B2NPC1RAB9AKMT2A
SCHEMBL9982521 0.86 HSD11B1 (0.63) HSD11B1HSD11B2NPC1RAB9AKMT2A
SCHEMBL3662022 0.86 HSD11B1 (0.77) HSD11B1HSD11B2SMN1; SMN2ALDH1A1MEN1
SCHEMBL9982199 0.86 HSD11B1 (0.48) HSD11B1PTPN11F12NPC1RAB9A
SCHEMBL8508946 0.84 HSD11B1 (0.61) HSD11B1HSD11B2NPC1RAB9AKMT2A
SCHEMBL3668822 0.82 HSD11B1 (0.66) HSD11B1HSD11B2NPC1RAB9AALDH1A1
SCHEMBL8511563 0.81 HSD11B1 (0.65) HSD11B1HSD11B2ALDH1A1HSD17B10
SCHEMBL8511324 0.81 HSD11B1 (0.65) HSD11B1HSD11B2NPC1RAB9ASMN1; SMN2
SCHEMBL3667504 0.81 HSD11B1 (0.86) HSD11B1HSD11B2
SCHEMBL9982812 0.81 HSD11B1 (0.64) HSD11B1HSD11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530473-B2 Tetrahydroquinoxaline urea derivatives as modulators of 11β-hydroxysteroid dehydrogenase type 1 SANOFI (FR) 2013-09-10 US disclosed
US-20120135958-A1 TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135958-A1 TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF CBR3, CBR1, OXGR1 HSD11B1 1963/4885HSD11B2 1686/4885PTPN11 2077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.